On Tuesday, Lumber Liquidators Holdings Inc (NYSE:LL)’s shares declined -1.40% to $21.18.
Lumber Liquidators Holdings Inc (LL) declared that it is integrating the leadership of its merchandising and marketing departments. Marco Q. Pescara, the Company’s Chief Marketing Officer since 2006, has been promoted to serve as the Company’s Chief Merchandising and Marketing Officer effective June 19, 2015. As the Company’s Chief Marketing Officer, Mr. Pescara developed the brand and customer strategy to communicate and deliver the Company’s core value proposition through all areas of marketing. In his new position, Mr. Pescara will lead the Company’s marketing and merchandising functions to provide a cohesive message and product assortment to the Company’s customers.
Lumber Liquidators Holdings, Inc., together with its auxiliaries, operates as a multi-channel specialty retailer of hardwood flooring, and hardwood flooring enhancements and accessories.
Charter Communications, Inc. (NASDAQ:CHTR)’s shares dropped -0.71% to $169.97.
Charter Communications, Inc. (CHTR) declared that Tom Rutledge, President and Chief Executive Officer, will take part in the Guggenheim TMT Symposium in New York, NY on Wednesday, June 17, 2015. Mr. Rutledge’s remarks are planned to start at 1:00 p.m. ET.
Charter Communications, Inc., through its subsidiaries, provides entertainment, information, and communications solutions to residential and commercial customers in the United States. The company offers cable video programming services, including basic and digital video, premium channels, on-demand, pay-per-view, high definition television, and digital video recorder services, as well as Charter TV App, which enables video customers to search and discover content on various devices, including the iPhone, iPad, iPod Touch, and Android based tablets.
At the end of Tuesday’s trade, TECO Energy, Inc. (NYSE:TE)‘s shares surged 0.22% to $17.83.
TECO Energy, Inc. (TE) has reached a non-binding letter of intent with a new buyer for the sale of all of its interest in TECO Coal LLC.
The sales agreement with Kentucky-based Cambrian Coal Corp. did not close on June 5, 2015, because the buyer could not satisfy the conditions precedent to closing, and that agreement is now terminable by either party. The new buyer does not expect to require external financing.
The transaction would be subject to the negotiation of a definitive agreement and obtaining third-party consents, and the parties presently expect to close on the sale on or before July 3.
TECO Energy, Inc., an electric and gas utility holding company, engages in the regulated electric and gas utility operations. It generates, purchases, transmits, distributes, and sells electric energy to retail customers, in addition to utilities and other resellers of electricity in West Central Florida; and has electric generating plants with a winter peak generating capacity of 4,668 megawatts.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX), ended its Tuesday’s trading session with 6.41% gain, and closed at $45.29.
Neurocrine Biosciences, Inc. (NBIX) declared that it has suspended two planned clinical studies of the Company’s CRF antagonist NBI-77860.
The two clinical studies that were halted comprise a single dose study in adolescent females with classic congenital adrenal hyperplasia and a multiple dose study in adults with classic congenital adrenal hyperplasia. The Company had not enrolled any subjects in either study and accordingly, there have been no adverse events stated.
The Company has also been informed by the FDA that the NBI-77860 clinical development program would be placed on partial clinical hold.
Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company’s products in clinical development stage comprise elagolix, which is in Phase III study for endometriosis; elagolix that is in Phase IIb study for uterine fibroids; Corticotropin-Releasing Factor Receptor1 Antagonist, which is in Phase I/II study for congenital adrenal hyperplasia and stress-related disorders; and Vesicular Monoamine Transporter 2 Inhibitor (VMAT2) that is in Phase III study for movement disorders, in addition to Phase I study for tourette syndrome. Its research programs comprise VMAT2 for movement disorders, bipolar disorders, and schizophrenia; gonadotropin-releasing hormone (GnRH) antagonists for men’s and women’s health, and oncology; antiepileptic drugs for epilepsy, essential tremor, and pain; and G Protein-Coupled receptors for other conditions.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
